Month: April 2021

Cette étape importante souligne la croissance de la production d’avions Global 7500 et le développement soutenu de ce programme d’avion d’affaires phare de l’industrie L’aile évoluée de l’avion Global 7500, fabriquée aux États-Unis, optimise la vitesse, l’autonomie, les performances sur courtes pistes et le vol exceptionnellement en douceur de l’avion Bombardier a récemment livré son 50e biréacteur d’affaires Global 7500, lequel suscite toujours un solide intérêt de clients du monde entierMONTRÉAL, 12 avr. 2021 (GLOBE NEWSWIRE) — Bombardier a annoncé aujourd’hui qu’elle fêtait la sortie d’usine de sa 100e aile d’avion d’affaires Global 7500, une étape importante pour cet appareil à l’avant-garde de l’industrie et pour les installations de l’entreprise à Red Oak (Texas), où cette aile évoluée est fabriquée. L’aile perfectionnée...

  ●   An estimated $7.8 million gross Revenue for March 2021, the highest in the history of the company  ●   This represents an estimated 41.8% increase over February gross Revenue of $5.5 million  ●   More than $6.2 million in Bitcoin and NDAU digital currency holdings recorded on the Balance Sheet as of March 31st, 2021 versus just over $1M in digital currency holdings as of February 28th, 2021       Eatontown, NJ, April 12, 2021 (GLOBE NEWSWIRE) — Investview, Inc. (OTCQB: INVU), a diversified financial technology company that through its subsidiaries and global distribution network provides financial technology, education tools, content, research, and management of digital asset technologies with a focus on Bitcoin mining and the new generation of digital assets, is pleased to announce a new record high combined...

PRESS RELEASE – REGULATED INFORMATION Information regarding the total number of voting rights and denominator Cambridge (UK) 12 April 2021: Global Graphics PLC (Euronext: GLOG) discloses voting rights information in accordance with article 15 of the Belgian Law of 2 May 2007. Pursuant to some employees exercising share options which have been settled out of treasury shares, there has been a reduction in treasury shares, thus an increase in voting rights (the denominator). Status as of 12 April 2021:Total share capital €13,163,895Total number of ordinary shares 32,909,737Total number of shares held in treasury * 94,996Total number of voting rights (the denominator) 32,814,741Total number of bonds convertible into securities conferring voting rights noneTotal number of rights, whether or not embodied in securities, to...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES TORONTO, April 12, 2021 (GLOBE NEWSWIRE) — Partners Value Split Corp. (the “Company”) announced today the completion of its previously announced issue of 6,000,000 Class AA Preferred Shares, Series 12 (the “Series 12 Preferred Shares”) at an offering price of $25.00 per Series 12 Preferred Share, raising gross proceeds of $150,000,000. The Series 12 Preferred Shares carry quarterly fixed cumulative preferential dividends representing a 4.40% annualized yield on the offering price and have a final maturity of February 29, 2028. The Series 12 Preferred Shares have been listed and posted for trading on the Toronto Stock Exchange under the symbol PVS.PR.J. The net proceeds of the offering will be used to fund the redemption of the Company’s Class AA...

Walmart found liable on three claims in lawsuit filed by Zest Labs Inc. Jury unanimously awards Ecoark Holdings, Inc. $115 million in damages SAN ANTONIO, April 12, 2021 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark” or the “Company”) (OTC: ZEST) announces that on Friday, April 9, 2021, a Little Rock, Arkansas jury awarded Ecoark and its wholly owned subsidiary, Zest Labs Inc. (“Zest”) a total of $115 million in damages in a lawsuit against Bentonville-based Walmart Inc. (“Walmart”) (NYSE: WMT), the world’s largest company as measured by annual revenue1. Walmart was found liable on three claims from the original lawsuit filed in August 2018. Specifically, the federal jury found that Walmart misappropriated Zest’s trade secrets, failed to comply with a written contract, and acted willfully and maliciously in...

LONDON, UK, April 12, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Argentum 47, Inc. (www.arg47.com) (OTC: ARGQ), and its fully-owned foreign subsidiary Cheshire Trafford UK Limited, is delighted to announce an increase in its funds under administration of circa U.S. $20,000,000 and the recruitment of two new Independent Financial Advisors, Mr. Tom Arthur and Mr. William Arthur.  Mr. Tom Arthur has nearly 40 years’ experience as an Independent Financial Advisor with various major International Investment Houses and for the last 20 years has been operating his own practice and book of clients. He is highly qualified beyond regulatory requirements, and provides a holistic service offering advice across the entire financial planning spectrum. Over this time, Tom has built a book of business that is to be incorporated into our U.K....

阿尔伯塔省卡尔加里, April 12, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp.（以下简称“Resverlogix”）（多伦多证券交易所股票代码：RVX）很高兴地宣布已从加拿大卫生部收到期待已久的“无异议函”。加拿大卫生部已批准关于对apabetalone进行新冠肺炎治疗临床试验的申请。这个计划中的2期试验将是一项开放标签研究，评估新冠肺炎住院患者在标准护理条件下口服apabetalone的安全性和疗效。Resverlogix总裁兼首席执行官Donald McCaffrey表示：“今天这个令人兴奋的消息是推进apabetalone作为新冠肺炎潜在高效治疗药物开发的重要一步。我们感谢加拿大卫生部对我们的申请进行迅速审查并予以批准。我们将继续与监管机构密切合作，将apabetalone推向市场，造福全球患者。” Resverlogix计划同时推进临床试验和药品制造项目，这种做法在Pfizer和Moderna的疫苗项目中都获得了成功。研究参与者将在接受标准护理的同时，在4周时间内每天接受两次apabetalone服药，或者仅接受标准护理，不服用apabetalone。研究结果的主要度量指标是世界卫生组织（WHO）临床改进顺序量表评分的变化。预计将有100名患者在加拿大和国外的多个地点参加研究，报名有望立即开始。研究开始前，将在clinicaltrials.gov网站发布完整的研究协议。 项目最新进展 apabetalone是一种处于试验阶段的， 第3期 临床候选药物，可提供4000多受试者的安全数据。Resverlogix已经宣布开放标签研究计划，以评估apabetalone在治疗新冠肺炎方面的安全性和疗效。 正如先前所公布, 2020年3月23日发表的一篇文章揭示了新冠病毒蛋白E与BET蛋白之间的相互作用。根据这一发现，Resverlogix发出一项 加强合作的号召，并由此得以建立多项伙伴关系，并同时发起内部临床前研究工作，以进一步确定和研究apabetalone治疗新冠肺炎感染的功效。 这项合作研究的结果发现，apabetalone有望通过一种独特的双重机制与新冠肺炎作斗争。首先，apabetalone治疗可以防止SARS-CoV-2感染人体细胞，其次，可以减少可能导致器官损伤和长期负面影响的炎症和细胞因子风暴反应。鉴于其双重机制和临床安全记录，多份经同行评议...

亞伯達省卡加利, April 12, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp.（「Resverlogix」）(TSX:RVX) 欣然宣佈已成功收到加拿大衛生部的「不反對書」。當局已批准 apabetalone 的 2019 冠狀病毒病臨床試驗申請。計劃的第 2 期試驗將是一項開放標籤研究、評估口服 apabetalone 的安全性和療效，以及結合 2019 冠狀病毒病住院患者的護理標準。Resverlogix 主席兼行政總裁 Donald McCaffrey 說：「今天令人振奮的公告是促進 apabetalone 作為 2019 冠狀病毒病潛在高效治療劑的臨床開發之重要一步。我們感謝加拿大衛生部迅速審查及批准我們的申請。我們將繼續與監管機構緊密合作，將 apabetalone 推向市場，以惠及全球患者。」 Resverlogix 計劃同時推進臨床及生產計劃，而輝瑞與莫德納疫苗計劃均已成功實現了。研究參與者將接受長達 4 週、每天兩次的 apabetalone 治療，同時接受標準的護理，或選擇接受不使用 apabetalone 的標準護理。這項研究的主要結果指標是世界衛生組織（WHO）臨床改善次序量表的變化。預計將在加拿大及國外的多個地點招募 100 名患者，並有望立即開始招募。完整的研究方案將在研究開始前上載在 clinicaltrials.gov 。 計劃更新 Apabetalone 是一項研究性 第三期臨床候選藥物，具有超過 4,000 名接受試驗者的安全性數據。Resverlogix 已宣佈計劃進行了一項開放標籤研究，以評估 apabetalone 治療 2019 冠狀病毒病的安全與療效。 如先前所宣佈，在 2020 年 3 月 23 日發佈的一篇文章顯示了嚴重急性呼吸系統綜合徵冠狀病毒 2（2019 冠狀病毒病）蛋白 E 與 BET 蛋白之間的相互作用。根據這項結果，Resverlogix 發出了進行合作的呼籲建立了多個合作夥伴關係，並同時開展了內部臨床前研究工作，以進一步表徵及研究...

TORONTO and CHICAGO and MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor Conference as well as the Stifel 2021 Canada Cross Sector Insight Conference in the month of April. Bloom Burton & Co. Healthcare Investor Conference Date: Tuesday, April 20, 2021Time: 11a.m. ETRegister for the virtual conference: click here The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian...